Your browser doesn't support javascript.
loading
Sphk2 RNAi nanoparticles suppress tumor growth via downregulating cancer cell derived exosomal microRNA.
Liang, Jinying; Zhang, Xinxin; He, Shufang; Miao, Yunqiu; Wu, Na; Li, Juan; Gan, Yong.
Afiliación
  • Liang J; Shanghai Institute of Materia Medica, Chinese Academy of Science, Shanghai 201203, China; Development of pharmaceutics, China Pharmaceutical University, Nanjing 210009, China; School of Pharmacy, Xinxiang Medical University, Xinxiang 453003, China.
  • Zhang X; Shanghai Institute of Materia Medica, Chinese Academy of Science, Shanghai 201203, China.
  • He S; Shanghai Institute of Materia Medica, Chinese Academy of Science, Shanghai 201203, China.
  • Miao Y; Shanghai Institute of Materia Medica, Chinese Academy of Science, Shanghai 201203, China.
  • Wu N; Development of pharmaceutics, China Pharmaceutical University, Nanjing 210009, China.
  • Li J; Development of pharmaceutics, China Pharmaceutical University, Nanjing 210009, China. Electronic address: lijuancpu@163.com.
  • Gan Y; Shanghai Institute of Materia Medica, Chinese Academy of Science, Shanghai 201203, China. Electronic address: ygan@simm.ac.cn.
J Control Release ; 286: 348-357, 2018 09 28.
Article en En | MEDLINE | ID: mdl-30077738

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Fosfotransferasas (Aceptor de Grupo Alcohol) / Carcinoma Hepatocelular / ARN Interferente Pequeño / Exosomas / Tratamiento con ARN de Interferencia / Neoplasias Hepáticas Límite: Animals / Humans / Male Idioma: En Revista: J Control Release Asunto de la revista: FARMACOLOGIA Año: 2018 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Fosfotransferasas (Aceptor de Grupo Alcohol) / Carcinoma Hepatocelular / ARN Interferente Pequeño / Exosomas / Tratamiento con ARN de Interferencia / Neoplasias Hepáticas Límite: Animals / Humans / Male Idioma: En Revista: J Control Release Asunto de la revista: FARMACOLOGIA Año: 2018 Tipo del documento: Article País de afiliación: China